c-Met targeted therapy of cholangiocarcinoma

Matei P. Socoteanu, Frank Mott, Gianfranco Alpini, Arthur E. Frankel

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Cholangiocarcinoma continues to be a challenging (disease to treat. Systemic therapy is used in unresectable disease, disease progression after surgery, and in the palliative setting. Unfortunately, results of multiple phase H trials have rarely yielded positive results. As data on the molecular carcinogenesis of cholangiocarcinoma is developing, we are more able to understand the disease process and can use this understanding to create unique targeted therapies. We reviewed the role of c-Met/hepatocyte growth factor (HGF) in the development of cholangiocarcinoma. Furthermore, we explored the use of the c-Met guided cascade as a target to treat cholangiocarcinoma. We reviewed the current use and options for future development of c-Met agents to treat this disease.

Original languageEnglish (US)
Pages (from-to)2990-2994
Number of pages5
JournalWorld Journal of Gastroenterology
Volume14
Issue number19
DOIs
StatePublished - May 21 2008

Fingerprint

Cholangiocarcinoma
Hepatocyte Growth Factor
Therapeutics
Palliative Care
Disease Progression
Carcinogenesis

Keywords

  • Chemotherapy
  • Cholangiocarcinoma
  • Target therapy
  • c-Met

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Socoteanu, M. P., Mott, F., Alpini, G., & Frankel, A. E. (2008). c-Met targeted therapy of cholangiocarcinoma. World Journal of Gastroenterology, 14(19), 2990-2994. https://doi.org/10.3748/wjg.14.2990

c-Met targeted therapy of cholangiocarcinoma. / Socoteanu, Matei P.; Mott, Frank; Alpini, Gianfranco; Frankel, Arthur E.

In: World Journal of Gastroenterology, Vol. 14, No. 19, 21.05.2008, p. 2990-2994.

Research output: Contribution to journalReview article

Socoteanu, MP, Mott, F, Alpini, G & Frankel, AE 2008, 'c-Met targeted therapy of cholangiocarcinoma', World Journal of Gastroenterology, vol. 14, no. 19, pp. 2990-2994. https://doi.org/10.3748/wjg.14.2990
Socoteanu MP, Mott F, Alpini G, Frankel AE. c-Met targeted therapy of cholangiocarcinoma. World Journal of Gastroenterology. 2008 May 21;14(19):2990-2994. https://doi.org/10.3748/wjg.14.2990
Socoteanu, Matei P. ; Mott, Frank ; Alpini, Gianfranco ; Frankel, Arthur E. / c-Met targeted therapy of cholangiocarcinoma. In: World Journal of Gastroenterology. 2008 ; Vol. 14, No. 19. pp. 2990-2994.
@article{9a06d21afa4e44f288122706dc41fff5,
title = "c-Met targeted therapy of cholangiocarcinoma",
abstract = "Cholangiocarcinoma continues to be a challenging (disease to treat. Systemic therapy is used in unresectable disease, disease progression after surgery, and in the palliative setting. Unfortunately, results of multiple phase H trials have rarely yielded positive results. As data on the molecular carcinogenesis of cholangiocarcinoma is developing, we are more able to understand the disease process and can use this understanding to create unique targeted therapies. We reviewed the role of c-Met/hepatocyte growth factor (HGF) in the development of cholangiocarcinoma. Furthermore, we explored the use of the c-Met guided cascade as a target to treat cholangiocarcinoma. We reviewed the current use and options for future development of c-Met agents to treat this disease.",
keywords = "Chemotherapy, Cholangiocarcinoma, Target therapy, c-Met",
author = "Socoteanu, {Matei P.} and Frank Mott and Gianfranco Alpini and Frankel, {Arthur E.}",
year = "2008",
month = "5",
day = "21",
doi = "10.3748/wjg.14.2990",
language = "English (US)",
volume = "14",
pages = "2990--2994",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "19",

}

TY - JOUR

T1 - c-Met targeted therapy of cholangiocarcinoma

AU - Socoteanu, Matei P.

AU - Mott, Frank

AU - Alpini, Gianfranco

AU - Frankel, Arthur E.

PY - 2008/5/21

Y1 - 2008/5/21

N2 - Cholangiocarcinoma continues to be a challenging (disease to treat. Systemic therapy is used in unresectable disease, disease progression after surgery, and in the palliative setting. Unfortunately, results of multiple phase H trials have rarely yielded positive results. As data on the molecular carcinogenesis of cholangiocarcinoma is developing, we are more able to understand the disease process and can use this understanding to create unique targeted therapies. We reviewed the role of c-Met/hepatocyte growth factor (HGF) in the development of cholangiocarcinoma. Furthermore, we explored the use of the c-Met guided cascade as a target to treat cholangiocarcinoma. We reviewed the current use and options for future development of c-Met agents to treat this disease.

AB - Cholangiocarcinoma continues to be a challenging (disease to treat. Systemic therapy is used in unresectable disease, disease progression after surgery, and in the palliative setting. Unfortunately, results of multiple phase H trials have rarely yielded positive results. As data on the molecular carcinogenesis of cholangiocarcinoma is developing, we are more able to understand the disease process and can use this understanding to create unique targeted therapies. We reviewed the role of c-Met/hepatocyte growth factor (HGF) in the development of cholangiocarcinoma. Furthermore, we explored the use of the c-Met guided cascade as a target to treat cholangiocarcinoma. We reviewed the current use and options for future development of c-Met agents to treat this disease.

KW - Chemotherapy

KW - Cholangiocarcinoma

KW - Target therapy

KW - c-Met

UR - http://www.scopus.com/inward/record.url?scp=48049100151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48049100151&partnerID=8YFLogxK

U2 - 10.3748/wjg.14.2990

DO - 10.3748/wjg.14.2990

M3 - Review article

C2 - 18494048

AN - SCOPUS:48049100151

VL - 14

SP - 2990

EP - 2994

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 19

ER -